Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 25.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 66,501 shares of the biopharmaceutical company's stock after buying an additional 13,376 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Royalty Pharma were worth $1,696,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in RPRX. Barclays PLC boosted its position in shares of Royalty Pharma by 16.3% during the third quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock worth $8,737,000 after buying an additional 43,339 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Royalty Pharma during the fourth quarter worth approximately $486,000. Ballentine Partners LLC acquired a new position in shares of Royalty Pharma during the fourth quarter worth approximately $200,000. Impact Partnership Wealth LLC acquired a new position in shares of Royalty Pharma during the fourth quarter worth approximately $467,000. Finally, Fifth Third Bancorp boosted its position in shares of Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 997 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several analyst reports. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Morgan Stanley initiated coverage on Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 target price on the stock. Finally, Wall Street Zen cut Royalty Pharma from a "buy" rating to a "hold" rating in a report on Tuesday, May 20th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $42.50.

Royalty Pharma Price Performance

NASDAQ:RPRX traded up $0.11 during midday trading on Thursday, hitting $32.74. 556,940 shares of the stock were exchanged, compared to its average volume of 4,618,546. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.31. The company has a market capitalization of $18.87 billion, a price-to-earnings ratio of 22.58, a P/E/G ratio of 2.31 and a beta of 0.49. The business has a 50-day moving average price of $32.34 and a two-hundred day moving average price of $30.29. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The firm had revenue of $839.00 million for the quarter, compared to analysts' expectations of $724.69 million. Sell-side analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.69%. Royalty Pharma's dividend payout ratio is currently 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.